Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
Rz7Wwxsn413dgabb
